Ribupatide

One peptide acting on two hormone receptors. HRS9531 and KAI-9531 name Ribupatide. It activates GLP-1 and GIP receptors, signals involved in appetite and blood-sugar regulation. Sharing those targets with Tirzepatide does not make it the same molecule or a two-drug blend. Kailera — Ribupatide development identity (Official context · Accessed 2026-09-30) · OBESITY PIPELINE LOOKS PROMISING — identity and outcome tradeoffs (Community discussion · Accessed 2026-09-30) · Hengrui — 2023 IDF Phase Ib injection summary (Official context · Accessed 2026-09-30)

Injection and tablet are different formulations. People ask whether this is another “tirz.” Weekly injections beneath the skin and daily tablets have separate development programs. Their milligrams cannot be converted directly; trial results do not identify a similarly named research vial. OBESITY PIPELINE LOOKS PROMISING — identity and outcome tradeoffs (Community discussion · Accessed 2026-09-30)

Source context — Kailera — Ribupatide development identity: Commercial developer page, not an independent efficacy review or U.S. approval label. Current Phase III development status is the basis for investigational wording. Formal results on the page are from the same cohorts reported in the dedicated releases, not extra evidence.

Source context — OBESITY PIPELINE LOOKS PROMISING — identity and outcome tradeoffs: Pipeline comparison discussion with mixed drugs; mood, energy and fatigue reports elsewhere concern other compounds and are excluded. No Ribupatide dose or proven muscle-preservation outcome. Identity facts are separately supported by developer material.

Source context — Hengrui — 2023 IDF Phase Ib injection summary: Sponsor conference summary, not full peer-reviewed blood-level tables. Human type 2 diabetes population; approximate injection value, not oral kinetics, subjective onset or community testing. No safety assurance inferred from short study.

Less food noise and earlier fullness. A blinded Kailera participant described fewer recurring food thoughts, feeling full sooner and less interest in snacks. These describe the hoped-for experience without establishing which study treatment caused it. Chance-Chain8819's blinded Kailera trial comment (Personal report · Accessed 2026-09-30)

A second participant describes the eating experience more directly. Chance-Chain8819 reported 500 g to 1 kg lost weekly, quieter food thoughts and less snacking. They linked constipation to insufficient fibre and indigestion to eating quickly. They suspected active treatment but could not confirm it; the comment names Kailera without a protocol or dose. Chance-Chain8819's blinded Kailera trial comment (Personal report · Accessed 2026-09-30)

One diary, two updates and an unknown assignment. G33kgirl13 reported 23 lb lost around four months, later 37 lb since April. They felt good, associated fewer problems with water and avoiding high-fat foods, and later described disrupted habits while still making better decisions. This is one timeline, not corroboration or a proven food rule. Starting journey! — G33kgirl13's blinded trial diary (Personal report · Accessed 2026-09-30)

Feeling better and digestive symptoms can coexist. The original participant described little nausea, later occasional nausea and heartburn; the newer account mentions constipation and indigestion. These do not establish symptom rates, causation or an easily tolerated amount. Starting journey! — G33kgirl13's blinded trial diary (Personal report · Accessed 2026-09-30) · Chance-Chain8819's blinded Kailera trial comment (Personal report · Accessed 2026-09-30)

Weight loss is the attraction; tolerability is part of the tradeoff. Pipeline commenters weigh faster loss against sustainable eating, muscle retention and fewer symptoms. These are competing priorities, not evidence that Ribupatide preserves muscle or outperforms alternatives. OBESITY PIPELINE LOOKS PROMISING — identity and outcome tradeoffs (Community discussion · Accessed 2026-09-30) · User-created incretin ranking and comments on follow-up length (Secondhand community claim · Accessed 2026-09-30)

Source context — Chance-Chain8819's blinded Kailera trial comment: Anonymous unverified self-identification as Kailera participant within Ribupatide discussion; no specific protocol, dose, start date or confirmed allocation. May be another Kailera program. Expectations and diet changes could contribute. Cannot establish Ribupatide causation or an independent confirmed treatment response.

Source context — Starting journey! — G33kgirl13's blinded trial diary: One anonymous author, two follow-ups. Allocation not verified; author mentions study drug, Wegovy and placebo at different points. No study identifier, medical records, first-dose clock or within-week duration. Reopened reply says 3 mg but not explicit frequency; once-weekly attribution retained separately from frozen how_it_feels_over_time[0]. Relative displayed dates are not converted into exact publication dates.

Source context — OBESITY PIPELINE LOOKS PROMISING — identity and outcome tradeoffs: Pipeline comparison discussion with mixed drugs; mood, energy and fatigue reports elsewhere concern other compounds and are excluded. No Ribupatide dose or proven muscle-preservation outcome. Identity facts are separately supported by developer material.

Source context — User-created incretin ranking and comments on follow-up length: Author promotes their own tracker, so this is self-promotional secondhand discussion, not independent clinical evidence or a user outcome. Trial percentages remain sponsor-origin claims and are not used as community dose measurements. One author's tracker/reposts are one origin.

3 mg in one blinded weekly-injection account. At about four months, the participant reported 3 mg; the existing account records once-weekly use. A possible next 4 or 5 mg was a plan, not completed use. This is neither confirmed Ribupatide exposure nor a suggested progression. Starting journey! — G33kgirl13's blinded trial diary (Personal report · Accessed 2026-09-30)

No independent community dose band established here. The other blinded account gives no amount. Trial-dose headlines are not a community regimen; oral and injectable quantities stay separate below. Chance-Chain8819's blinded Kailera trial comment (Personal report · Accessed 2026-09-30) · User-created incretin ranking and comments on follow-up length (Secondhand community claim · Accessed 2026-09-30)

China injection studies: 6 mg and 8 mg belong to different trials. Phase III tested 2, 4 or 6 mg weekly for 48 weeks: 6 mg averaged 17.7% loss versus 1.4% placebo including discontinuations and other treatments; assuming continued treatment yielded 19.2%. Separate Phase II 8 mg weekly reported 23.6% at 36 weeks assuming adherence, versus 1.8% placebo. Hengrui and Kailera — China Phase III additional results (Official context · Accessed 2026-09-30)

Oral Phase II: daily tablet amounts. In 166 Chinese adults without diabetes, 10, 25 or 50 mg once daily for 26 weeks produced mean losses of 6.9%, 12.1% and 12.1%, versus 2.3% placebo, in the analysis assuming treatment adherence. Nausea and vomiting were reported. These results cannot predict an injectable feel curve. Hengrui and Kailera — Oral Phase II topline (Official context · Accessed 2026-09-30)

Global KaiNETIC: weekly injection through 76 weeks. The three Phase III trials evaluate doses up to 10 mg beneath the skin once weekly, with dose increases followed by maintenance. Their length is a study design, not an established community cycle. Kailera — KaiNETIC first participants randomized (Official context · Accessed 2026-09-30)

Higher-dose U.S. Phase IIb is a separate question. The 48-week trial enrolled 264 adults with BMI at least 35 and no diabetes, testing 10, 13, 16 or 20 mg once-weekly injections. The sponsor anticipated 2027 data and 2028 KaiNETIC data; neither forecast is a result or an approval date. Kailera — Q2 2026 high-dose trial and readout forecasts (Official context · Accessed 2026-09-30)

Source context — Starting journey! — G33kgirl13's blinded trial diary: One anonymous author, two follow-ups. Allocation not verified; author mentions study drug, Wegovy and placebo at different points. No study identifier, medical records, first-dose clock or within-week duration. Reopened reply says 3 mg but not explicit frequency; once-weekly attribution retained separately from frozen how_it_feels_over_time[0]. Relative displayed dates are not converted into exact publication dates.

Source context — Chance-Chain8819's blinded Kailera trial comment: Anonymous unverified self-identification as Kailera participant within Ribupatide discussion; no specific protocol, dose, start date or confirmed allocation. May be another Kailera program. Expectations and diet changes could contribute. Cannot establish Ribupatide causation or an independent confirmed treatment response.

Source context — User-created incretin ranking and comments on follow-up length: Author promotes their own tracker, so this is self-promotional secondhand discussion, not independent clinical evidence or a user outcome. Trial percentages remain sponsor-origin claims and are not used as community dose measurements. One author's tracker/reposts are one origin.

Source context — Hengrui and Kailera — China Phase III additional results: Sponsor-origin trials and press summary; different trial phases/cohorts and analysis assumptions must not merge. Phase II 23.6% uses an adherence/hypothetical analysis; not the Phase III treatment-policy number. Developer product page instead displays 1.7% Phase II placebo, a rounding/source discrepancy recorded without averaging.

Source context — Hengrui and Kailera — Oral Phase II topline: Commercial sponsor topline for NCT06841445, not community oral experience or proof of better tolerability. Efficacy analysis assumes adherence and excludes later data after premature discontinuation/other weight-loss treatment. Daily oral milligrams cannot convert to injected milligrams.

Source context — Kailera — KaiNETIC first participants randomized: Study design, not outcomes or community cycle/dose advice. Maximum amount does not establish effectiveness or tolerability. Broad population comparison requires results, not simply enrollment.

Source context — Kailera — Q2 2026 high-dose trial and readout forecasts: Sponsor forecasts may change; enrollment and planned readout are not efficacy or approval. Distinct study from China results and KaiNETIC Phase III.

No reliable first-dose clock reported. One diary reports months of progress; the newer account describes weekly loss since starting. Neither times the first appetite change after an injection. Later positive updates cannot establish an hours-versus-days onset. Starting journey! — G33kgirl13's blinded trial diary (Personal report · Accessed 2026-09-30) · Chance-Chain8819's blinded Kailera trial comment (Personal report · Accessed 2026-09-30)

Within-week appetite and symptom timing are unknown. Neither account tracks stronger days, end-of-week hunger or how long symptoms lasted after each injection. Months of follow-up are not the duration of one dose. Starting journey! — G33kgirl13's blinded trial diary (Personal report · Accessed 2026-09-30) · Chance-Chain8819's blinded Kailera trial comment (Personal report · Accessed 2026-09-30)

About one week is a company-reported injection half-life. Hengrui's 2023 Phase Ib summary in type 2 diabetes reports this approximate value after a four-week study. After a single injection, the highest blood levels occurred at a median 72.0–94.8 hours. Peak blood level is not subjective onset, and neither measurement transfers directly to oral tablets. Hengrui — 2023 IDF Phase Ib injection summary (Official context · Accessed 2026-09-30)

Source context — Starting journey! — G33kgirl13's blinded trial diary: One anonymous author, two follow-ups. Allocation not verified; author mentions study drug, Wegovy and placebo at different points. No study identifier, medical records, first-dose clock or within-week duration. Reopened reply says 3 mg but not explicit frequency; once-weekly attribution retained separately from frozen how_it_feels_over_time[0]. Relative displayed dates are not converted into exact publication dates.

Source context — Chance-Chain8819's blinded Kailera trial comment: Anonymous unverified self-identification as Kailera participant within Ribupatide discussion; no specific protocol, dose, start date or confirmed allocation. May be another Kailera program. Expectations and diet changes could contribute. Cannot establish Ribupatide causation or an independent confirmed treatment response.

Source context — Hengrui — 2023 IDF Phase Ib injection summary: Sponsor conference summary, not full peer-reviewed blood-level tables. Human type 2 diabetes population; approximate injection value, not oral kinetics, subjective onset or community testing. No safety assurance inferred from short study.

Months of study participation, not a repeat-cycle template. The original participant posted beyond four months. Neither account documents an off-period, maintenance amount, taper or restart. Slipping on habits does not establish stopping injections, withdrawal or regain. Starting journey! — G33kgirl13's blinded trial diary (Personal report · Accessed 2026-09-30) · Chance-Chain8819's blinded Kailera trial comment (Personal report · Accessed 2026-09-30)

China injection studies: 6 mg and 8 mg belong to different trials. Phase III tested 2, 4 or 6 mg weekly for 48 weeks: 6 mg averaged 17.7% loss versus 1.4% placebo including discontinuations and other treatments; assuming continued treatment yielded 19.2%. Separate Phase II 8 mg weekly reported 23.6% at 36 weeks assuming adherence, versus 1.8% placebo. Hengrui and Kailera — China Phase III additional results (Official context · Accessed 2026-09-30)

Oral Phase II: daily tablet amounts. In 166 Chinese adults without diabetes, 10, 25 or 50 mg once daily for 26 weeks produced mean losses of 6.9%, 12.1% and 12.1%, versus 2.3% placebo, in the analysis assuming treatment adherence. Nausea and vomiting were reported. These results cannot predict an injectable feel curve. Hengrui and Kailera — Oral Phase II topline (Official context · Accessed 2026-09-30)

Global KaiNETIC: weekly injection through 76 weeks. The three Phase III trials evaluate doses up to 10 mg beneath the skin once weekly, with dose increases followed by maintenance. Their length is a study design, not an established community cycle. Kailera — KaiNETIC first participants randomized (Official context · Accessed 2026-09-30)

Higher-dose U.S. Phase IIb is a separate question. The 48-week trial enrolled 264 adults with BMI at least 35 and no diabetes, testing 10, 13, 16 or 20 mg once-weekly injections. The sponsor anticipated 2027 data and 2028 KaiNETIC data; neither forecast is a result or an approval date. Kailera — Q2 2026 high-dose trial and readout forecasts (Official context · Accessed 2026-09-30)

Source context — Starting journey! — G33kgirl13's blinded trial diary: One anonymous author, two follow-ups. Allocation not verified; author mentions study drug, Wegovy and placebo at different points. No study identifier, medical records, first-dose clock or within-week duration. Reopened reply says 3 mg but not explicit frequency; once-weekly attribution retained separately from frozen how_it_feels_over_time[0]. Relative displayed dates are not converted into exact publication dates.

Source context — Chance-Chain8819's blinded Kailera trial comment: Anonymous unverified self-identification as Kailera participant within Ribupatide discussion; no specific protocol, dose, start date or confirmed allocation. May be another Kailera program. Expectations and diet changes could contribute. Cannot establish Ribupatide causation or an independent confirmed treatment response.

Source context — Hengrui and Kailera — China Phase III additional results: Sponsor-origin trials and press summary; different trial phases/cohorts and analysis assumptions must not merge. Phase II 23.6% uses an adherence/hypothetical analysis; not the Phase III treatment-policy number. Developer product page instead displays 1.7% Phase II placebo, a rounding/source discrepancy recorded without averaging.

Source context — Hengrui and Kailera — Oral Phase II topline: Commercial sponsor topline for NCT06841445, not community oral experience or proof of better tolerability. Efficacy analysis assumes adherence and excludes later data after premature discontinuation/other weight-loss treatment. Daily oral milligrams cannot convert to injected milligrams.

Source context — Kailera — KaiNETIC first participants randomized: Study design, not outcomes or community cycle/dose advice. Maximum amount does not establish effectiveness or tolerability. Broad population comparison requires results, not simply enrollment.

Source context — Kailera — Q2 2026 high-dose trial and readout forecasts: Sponsor forecasts may change; enrollment and planned readout are not efficacy or approval. Distinct study from China results and KaiNETIC Phase III.

Comparisons, not combinations: Tirzepatide, enicepatide and mazdutide appear as alternatives in discussion; those comparisons do not document a ribupatide stack. [community]

A research label is not the study drug. HRS-9531 labels cannot establish identity, concentration or trial-product equivalence. Oral amounts are not injectable amounts. Ribupatide remains investigational in the U.S.; comparisons with other compounds do not support stacking them. Kailera — Ribupatide development identity (Official context · Accessed 2026-09-30)

Source context — Kailera — Ribupatide development identity: Commercial developer page, not an independent efficacy review or U.S. approval label. Current Phase III development status is the basis for investigational wording. Formal results on the page are from the same cohorts reported in the dedicated releases, not extra evidence.

Feeling better and digestive symptoms can coexist. The original participant described little nausea, later occasional nausea and heartburn; the newer account mentions constipation and indigestion. These do not establish symptom rates, causation or an easily tolerated amount. Starting journey! — G33kgirl13's blinded trial diary (Personal report · Accessed 2026-09-30) · Chance-Chain8819's blinded Kailera trial comment (Personal report · Accessed 2026-09-30)

Study safeguards matter. KaiNETIC-1 excludes pancreatitis, significant stomach-emptying disorders, medullary thyroid cancer, MEN2 (an inherited endocrine-cancer syndrome) and recent other-incretin treatment. Screening boundaries do not establish combination, pregnancy or years-long safety. ClinicalTrials.gov — KaiNETIC-1 eligibility criteria (Official context · Accessed 2026-09-30)

A research label is not the study drug. HRS-9531 labels cannot establish identity, concentration or trial-product equivalence. Oral amounts are not injectable amounts. Ribupatide remains investigational in the U.S.; comparisons with other compounds do not support stacking them. Kailera — Ribupatide development identity (Official context · Accessed 2026-09-30)

Percentages need their original trial attached. A user-created ranking repeats 23.6% while acknowledging different populations, doses and follow-up; replies request weeks. These headlines cannot predict individual loss or establish a head-to-head ranking. Confirmed Ribupatide nonresponse and stopping outcomes remain missing here. User-created incretin ranking and comments on follow-up length (Secondhand community claim · Accessed 2026-09-30)

China injection studies: 6 mg and 8 mg belong to different trials. Phase III tested 2, 4 or 6 mg weekly for 48 weeks: 6 mg averaged 17.7% loss versus 1.4% placebo including discontinuations and other treatments; assuming continued treatment yielded 19.2%. Separate Phase II 8 mg weekly reported 23.6% at 36 weeks assuming adherence, versus 1.8% placebo. Hengrui and Kailera — China Phase III additional results (Official context · Accessed 2026-09-30)

Source context — Starting journey! — G33kgirl13's blinded trial diary: One anonymous author, two follow-ups. Allocation not verified; author mentions study drug, Wegovy and placebo at different points. No study identifier, medical records, first-dose clock or within-week duration. Reopened reply says 3 mg but not explicit frequency; once-weekly attribution retained separately from frozen how_it_feels_over_time[0]. Relative displayed dates are not converted into exact publication dates.

Source context — Chance-Chain8819's blinded Kailera trial comment: Anonymous unverified self-identification as Kailera participant within Ribupatide discussion; no specific protocol, dose, start date or confirmed allocation. May be another Kailera program. Expectations and diet changes could contribute. Cannot establish Ribupatide causation or an independent confirmed treatment response.

Source context — ClinicalTrials.gov — KaiNETIC-1 eligibility criteria: Sponsor-supplied public registration, not results or a complete contraindication list. Additional protocol criteria may apply. Public page exposed only its shell; actual criteria came from API. Absence of pregnancy outcomes or combination evidence is not proof of safety or harm.

Source context — Kailera — Ribupatide development identity: Commercial developer page, not an independent efficacy review or U.S. approval label. Current Phase III development status is the basis for investigational wording. Formal results on the page are from the same cohorts reported in the dedicated releases, not extra evidence.

Source context — User-created incretin ranking and comments on follow-up length: Author promotes their own tracker, so this is self-promotional secondhand discussion, not independent clinical evidence or a user outcome. Trial percentages remain sponsor-origin claims and are not used as community dose measurements. One author's tracker/reposts are one origin.

Source context — Hengrui and Kailera — China Phase III additional results: Sponsor-origin trials and press summary; different trial phases/cohorts and analysis assumptions must not merge. Phase II 23.6% uses an adherence/hypothetical analysis; not the Phase III treatment-policy number. Developer product page instead displays 1.7% Phase II placebo, a rounding/source discrepancy recorded without averaging.